Dry Eye Syndrome Treatment - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Indication (Evaporative Dry Eye Syndrome v/s Aqueous Deficient Dry Eye Syndrome), By Product Type (Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, and Others), By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, and Ointments), By Type (Prescription v/s Over The Counter), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region, and Competition
The Global Dry Eye Syndrome Treatment Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing prevalence of dry eye syndrome due to certain diseases, such as rheumatoid arthritis, thyroid diseases, and lupus, across the globe. Besides, increasing drug approvals and launches of new eye drops, along with rising research and development activities in the healthcare sector for the development of new treatments for dry eye diseases across the globe, are further expected to support the dry eye syndrome treatment market during the forecast period. In the U.S., more than 120,000 are blind from glaucoma, accounting for 9% to 12% of all cases of blindness. Also, the growing development of intranasal tear neurostimulation devices, which will increase tear production in adults, along with the development of new treatment modalities, will boost the market growth during the forecasted period. Also, the rising number of new players in the market is anticipated to lead the regulatory approvals and further propel the growth of the market.
Growing Prevalence of Dry Eye Disease
The most common dry eye disease is a chronic ophthalmic disorder which has a high prevalence rate among the aging population compared to adults. Growing usage of screens, consuming improper diet, growing usage of contact lenses, and the rising number of LASIK surgeries across the globe will further drive the market growth in the forecast period. Due to increasing age, the ability of the lachrymal glands to produce tears decreases, which leads to a dry eye condition which is one of the key factors contributing to the demand for dry eye syndrome and driving the growth of the market during the forecasted period. Based on data from the National Health and Wellness Survey, 6.8 percent of the United States adult population (approximately 16.4 million people) have been diagnosed with DED.
Growing investment in Healthcare Industry
Furthermore, growing initiatives by public and private organizations to spread awareness about the new treatment of dry eye syndrome will propel the dry eye syndrome treatment market over the years. Changing dietary patterns and sedentary lifestyles are the factors that will influence the market dynamics during the forecast period. Increasing the number of eye care centers across the globe and growing penetration of the OTC eyedrop market across developing regions will further boost the market growth in the forecast period. In January 2022, Sun Pharma announced the launch of a dry eye treatment product named Cequa in Canada. It is the first dry eye disease treatment that is delivered with nano micellar (NCELL) technology. This technology enhances the bioavailability as well as physiochemical stability of cyclosporine to raise ocular tissue penetration.
Market Segmentation
The Global Dry Eye Syndrome Treatment Market can be segmented by indication, product type, dosage form, type, distribution channel, and by region. Based on indication, the market can be divided into Evaporative Dry Eye Syndrome and Aqueous Deficient Dry Eye Syndrome. Based on product type, the market can be differentiated into Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, and Others. Based on dosage form, the market can be grouped into Gels, Eye Solutions, Capsules & Tablets, Eye Drops, and Ointments. Based on Type, the market can be divided into Prescription and Over Counter. Based on distribution channels, the market can be segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global dry eye syndrome treatment market on account of the growing demand for dry eye treatment in the country.
Recent Development
Johnson & Johnson, AbbVie Inc., Bausch Health Companies Inc., Novartis AG, Sun Pharmaceuticals Industries Limited, Santen Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., Alcon Inc., GlaxoSmithKline plc. are some of the leading players operating in the Global Dry Eye Syndrome Treatment Market.
Report Scope:
In this report, global dry eye syndrome treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in Global Dry Eye Syndrome Treatment Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Growing Prevalence of Dry Eye Disease
The most common dry eye disease is a chronic ophthalmic disorder which has a high prevalence rate among the aging population compared to adults. Growing usage of screens, consuming improper diet, growing usage of contact lenses, and the rising number of LASIK surgeries across the globe will further drive the market growth in the forecast period. Due to increasing age, the ability of the lachrymal glands to produce tears decreases, which leads to a dry eye condition which is one of the key factors contributing to the demand for dry eye syndrome and driving the growth of the market during the forecasted period. Based on data from the National Health and Wellness Survey, 6.8 percent of the United States adult population (approximately 16.4 million people) have been diagnosed with DED.
Growing investment in Healthcare Industry
Furthermore, growing initiatives by public and private organizations to spread awareness about the new treatment of dry eye syndrome will propel the dry eye syndrome treatment market over the years. Changing dietary patterns and sedentary lifestyles are the factors that will influence the market dynamics during the forecast period. Increasing the number of eye care centers across the globe and growing penetration of the OTC eyedrop market across developing regions will further boost the market growth in the forecast period. In January 2022, Sun Pharma announced the launch of a dry eye treatment product named Cequa in Canada. It is the first dry eye disease treatment that is delivered with nano micellar (NCELL) technology. This technology enhances the bioavailability as well as physiochemical stability of cyclosporine to raise ocular tissue penetration.
Market Segmentation
The Global Dry Eye Syndrome Treatment Market can be segmented by indication, product type, dosage form, type, distribution channel, and by region. Based on indication, the market can be divided into Evaporative Dry Eye Syndrome and Aqueous Deficient Dry Eye Syndrome. Based on product type, the market can be differentiated into Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, and Others. Based on dosage form, the market can be grouped into Gels, Eye Solutions, Capsules & Tablets, Eye Drops, and Ointments. Based on Type, the market can be divided into Prescription and Over Counter. Based on distribution channels, the market can be segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global dry eye syndrome treatment market on account of the growing demand for dry eye treatment in the country.
Recent Development
- In October 2019, Sun Pharmaceutical Industries Ltd launched a product called CEQUA for the treatment of dry eye syndrome in the U.S. and the highest concentration of cyclosporine for ophthalmic use, which is approved by the U.S. FDA.
- In July 2019, Novartis announced the completion of the successful acquisition of Xiidra 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by controlling the inflammation caused by the disease.
Johnson & Johnson, AbbVie Inc., Bausch Health Companies Inc., Novartis AG, Sun Pharmaceuticals Industries Limited, Santen Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Oyster Point Pharma, Inc., Alcon Inc., GlaxoSmithKline plc. are some of the leading players operating in the Global Dry Eye Syndrome Treatment Market.
Report Scope:
In this report, global dry eye syndrome treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
- Dry Eye Syndrome Treatment Market, By Indication:
- Evaporative Dry Eye Syndrome
- Aqueous Deficient Dry Eye Syndrome
- Dry Eye Syndrome Treatment Market, By Product Type:
- Cyclosporine
- Topical Corticosteroids
- Artificial Tears
- Punctal Plugs
- Others
- Dry Eye Syndrome Treatment Market, By Dosage Form:
- Gels
- Eye Solutions
- Capsules & Tablets
- Eye Drops
- Ointments
- Dry Eye Syndrome Treatment Market, By Type:
- Prescription
- Over The Counter
- Dry Eye Syndrome Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Dry Eye Syndrome Treatment Market, By Region:
- North America
- United States
- Mexico
- Canada
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in Global Dry Eye Syndrome Treatment Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. CLINICAL TRIAL ANALYSIS
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. GLOBAL DRY EYE SYNDROME TREATMENT MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indication (Evaporative Dry Eye Syndrome v/s Aqueous Deficient Dry Eye Syndrome)
6.2.2. By Product Type (Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Others)
6.2.3. By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments)
6.2.4. By Type (Prescription v/s Over The Counter)
6.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
6.2.6. By Region
6.2.7. By Company (2022)
6.3. Market Map
6.3.1. By Indication
6.3.2. By Product Type
6.3.3. By Dosage Form
6.3.4. By Type
6.3.5. By Distribution Channel
6.3.6. By Region
7. NORTH AMERICA DRY EYE SYNDROME TREATMENT MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication
7.2.2. By Product Type
7.2.3. By Dosage Form
7.2.4. By Type
7.2.5. By Distribution Channel
7.2.6. By Country
7.3. North America: Country Analysis
7.3.1. United States Dry Eye Syndrome Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Indication
7.3.1.2.2. By Product Type
7.3.1.2.3. By Dosage Form
7.3.1.2.4. By Type
7.3.1.2.5. By Distribution Channel
7.3.2. Canada Dry Eye Syndrome Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Indication
7.3.2.2.2. By Product Type
7.3.2.2.3. By Dosage Form
7.3.2.2.4. By Type
7.3.2.2.5. By Distribution Channel
7.3.3. Mexico Dry Eye Syndrome Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Indication
7.3.3.2.2. By Product Type
7.3.3.2.3. By Dosage Form
7.3.3.2.4. By Type
7.3.3.2.5. By Distribution Channel
8. EUROPE DRY EYE SYNDROME TREATMENT MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication
8.2.2. By Product Type
8.2.3. By Dosage Form
8.2.4. By Type
8.2.5. By Distribution Channel
8.2.6. By Country
8.3. Europe: Country Analysis
8.3.1. France Dry Eye Syndrome Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indication
8.3.1.2.2. By Product Type
8.3.1.2.3. By Dosage Form
8.3.1.2.4. By Type
8.3.1.2.5. By Distribution Channel
8.3.2. Germany Dry Eye Syndrome Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indication
8.3.2.2.2. By Product Type
8.3.2.2.3. By Dosage Form
8.3.2.2.4. By Type
8.3.2.2.5. By Distribution Channel
8.3.3. United Kingdom Dry Eye Syndrome Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indication
8.3.3.2.2. By Product Type
8.3.3.2.3. By Dosage Form
8.3.3.2.4. By Type
8.3.3.2.5. By Distribution Channel
8.3.4. Italy Dry Eye Syndrome Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Indication
8.3.4.2.2. By Product Type
8.3.4.2.3. By Dosage Form
8.3.4.2.4. By Type
8.3.4.2.5. By Distribution Channel
8.3.5. Spain Dry Eye Syndrome Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Indication
8.3.5.2.2. By Product Type
8.3.5.2.3. By Dosage Form
8.3.5.2.4. By Type
8.3.5.2.5. By Distribution Channel
9. ASIA-PACIFIC DRY EYE SYNDROME TREATMENT MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indication
9.2.2. By Product Type
9.2.3. By Dosage Form
9.2.4. By Type
9.2.5. By Distribution Channel
9.2.6. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Dry Eye Syndrome Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indication
9.3.1.2.2. By Product Type
9.3.1.2.3. By Dosage Form
9.3.1.2.4. By Type
9.3.1.2.5. By Distribution Channel
9.3.2. India Dry Eye Syndrome Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indication
9.3.2.2.2. By Product Type
9.3.2.2.3. By Dosage Form
9.3.2.2.4. By Type
9.3.2.2.5. By Distribution Channel
9.3.3. Japan Dry Eye Syndrome Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indication
9.3.3.2.2. By Product Type
9.3.3.2.3. By Dosage Form
9.3.3.2.4. By Type
9.3.3.2.5. By Distribution Channel
9.3.4. South Korea Dry Eye Syndrome Treatment Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Indication
9.3.4.2.2. By Product Type
9.3.4.2.3. By Dosage Form
9.3.4.2.4. By Type
9.3.4.2.5. By Distribution Channel
9.3.5. Australia Dry Eye Syndrome Treatment Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Indication
9.3.5.2.2. By Product Type
9.3.5.2.3. By Dosage Form
9.3.5.2.4. By Type
9.3.5.2.5. By Distribution Channel
10. SOUTH AMERICA DRY EYE SYNDROME TREATMENT MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indication
10.2.2. By Product Type
10.2.3. By Dosage Form
10.2.4. By Type
10.2.5. By Distribution Channel
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Dry Eye Syndrome Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Indication
10.3.1.2.2. By Product Type
10.3.1.2.3. By Dosage Form
10.3.1.2.4. By Type
10.3.1.2.5. By Distribution Channel
10.3.2. Argentina Dry Eye Syndrome Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Indication
10.3.2.2.2. By Product Type
10.3.2.2.3. By Dosage Form
10.3.2.2.4. By Type
10.3.2.2.5. By Distribution Channel
10.3.3. Colombia Dry Eye Syndrome Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Indication
10.3.3.2.2. By Product Type
10.3.3.2.3. By Dosage Form
10.3.3.2.4. By Type
10.3.3.2.5. By Distribution Channel
11. MIDDLE EAST AND AFRICA DRY EYE SYNDROME TREATMENT MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Indication
11.2.2. By Product Type
11.2.3. By Dosage Form
11.2.4. By Type
11.2.5. By Distribution Channel
11.2.6. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Dry Eye Syndrome Treatment Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Indication
11.3.1.2.2. By Product Type
11.3.1.2.3. By Dosage Form
11.3.1.2.4. By Type
11.3.1.2.5. By Distribution Channel
11.3.2. Saudi Arabia Dry Eye Syndrome Treatment Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Indication
11.3.2.2.2. By Product Type
11.3.2.2.3. By Dosage Form
11.3.2.2.4. By Type
11.3.2.2.5. By Distribution Channel
11.3.3. UAE Dry Eye Syndrome Treatment Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Indication
11.3.3.2.2. By Product Type
11.3.3.2.3. By Dosage Form
11.3.3.2.4. By Type
11.3.3.2.5. By Distribution Channel
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
13.1. Recent Developments
13.2. Mergers & Acquisitions
13.3. Product Launches
14. COMPETITIVE LANDSCAPE
14.1. Business Overview
14.2. Product Offerings
14.3. Recent Developments
14.4. Financials (As Reported)
14.5. Key Personnel
14.6. SWOT Analysis
14.6.1. Johnson & Johnson
14.6.2. AbbVie Inc.
14.6.3. Bausch Health Companies Inc.
14.6.4. Novartis AG
14.6.5. Sun Pharmaceuticals Industries Limited
14.6.6. Santen Pharmaceutical Co., Ltd.
14.6.7. Otsuka Pharmaceutical Co., Ltd.
14.6.8. Oyster Point Pharma, Inc.
14.6.9. Alcon Inc.
14.6.10. GlaxoSmithKline plc.
15. STRATEGIC RECOMMENDATIONS
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. CLINICAL TRIAL ANALYSIS
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. GLOBAL DRY EYE SYNDROME TREATMENT MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indication (Evaporative Dry Eye Syndrome v/s Aqueous Deficient Dry Eye Syndrome)
6.2.2. By Product Type (Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Others)
6.2.3. By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments)
6.2.4. By Type (Prescription v/s Over The Counter)
6.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
6.2.6. By Region
6.2.7. By Company (2022)
6.3. Market Map
6.3.1. By Indication
6.3.2. By Product Type
6.3.3. By Dosage Form
6.3.4. By Type
6.3.5. By Distribution Channel
6.3.6. By Region
7. NORTH AMERICA DRY EYE SYNDROME TREATMENT MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication
7.2.2. By Product Type
7.2.3. By Dosage Form
7.2.4. By Type
7.2.5. By Distribution Channel
7.2.6. By Country
7.3. North America: Country Analysis
7.3.1. United States Dry Eye Syndrome Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Indication
7.3.1.2.2. By Product Type
7.3.1.2.3. By Dosage Form
7.3.1.2.4. By Type
7.3.1.2.5. By Distribution Channel
7.3.2. Canada Dry Eye Syndrome Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Indication
7.3.2.2.2. By Product Type
7.3.2.2.3. By Dosage Form
7.3.2.2.4. By Type
7.3.2.2.5. By Distribution Channel
7.3.3. Mexico Dry Eye Syndrome Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Indication
7.3.3.2.2. By Product Type
7.3.3.2.3. By Dosage Form
7.3.3.2.4. By Type
7.3.3.2.5. By Distribution Channel
8. EUROPE DRY EYE SYNDROME TREATMENT MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication
8.2.2. By Product Type
8.2.3. By Dosage Form
8.2.4. By Type
8.2.5. By Distribution Channel
8.2.6. By Country
8.3. Europe: Country Analysis
8.3.1. France Dry Eye Syndrome Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indication
8.3.1.2.2. By Product Type
8.3.1.2.3. By Dosage Form
8.3.1.2.4. By Type
8.3.1.2.5. By Distribution Channel
8.3.2. Germany Dry Eye Syndrome Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indication
8.3.2.2.2. By Product Type
8.3.2.2.3. By Dosage Form
8.3.2.2.4. By Type
8.3.2.2.5. By Distribution Channel
8.3.3. United Kingdom Dry Eye Syndrome Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indication
8.3.3.2.2. By Product Type
8.3.3.2.3. By Dosage Form
8.3.3.2.4. By Type
8.3.3.2.5. By Distribution Channel
8.3.4. Italy Dry Eye Syndrome Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Indication
8.3.4.2.2. By Product Type
8.3.4.2.3. By Dosage Form
8.3.4.2.4. By Type
8.3.4.2.5. By Distribution Channel
8.3.5. Spain Dry Eye Syndrome Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Indication
8.3.5.2.2. By Product Type
8.3.5.2.3. By Dosage Form
8.3.5.2.4. By Type
8.3.5.2.5. By Distribution Channel
9. ASIA-PACIFIC DRY EYE SYNDROME TREATMENT MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indication
9.2.2. By Product Type
9.2.3. By Dosage Form
9.2.4. By Type
9.2.5. By Distribution Channel
9.2.6. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Dry Eye Syndrome Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indication
9.3.1.2.2. By Product Type
9.3.1.2.3. By Dosage Form
9.3.1.2.4. By Type
9.3.1.2.5. By Distribution Channel
9.3.2. India Dry Eye Syndrome Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indication
9.3.2.2.2. By Product Type
9.3.2.2.3. By Dosage Form
9.3.2.2.4. By Type
9.3.2.2.5. By Distribution Channel
9.3.3. Japan Dry Eye Syndrome Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indication
9.3.3.2.2. By Product Type
9.3.3.2.3. By Dosage Form
9.3.3.2.4. By Type
9.3.3.2.5. By Distribution Channel
9.3.4. South Korea Dry Eye Syndrome Treatment Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Indication
9.3.4.2.2. By Product Type
9.3.4.2.3. By Dosage Form
9.3.4.2.4. By Type
9.3.4.2.5. By Distribution Channel
9.3.5. Australia Dry Eye Syndrome Treatment Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Indication
9.3.5.2.2. By Product Type
9.3.5.2.3. By Dosage Form
9.3.5.2.4. By Type
9.3.5.2.5. By Distribution Channel
10. SOUTH AMERICA DRY EYE SYNDROME TREATMENT MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indication
10.2.2. By Product Type
10.2.3. By Dosage Form
10.2.4. By Type
10.2.5. By Distribution Channel
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Dry Eye Syndrome Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Indication
10.3.1.2.2. By Product Type
10.3.1.2.3. By Dosage Form
10.3.1.2.4. By Type
10.3.1.2.5. By Distribution Channel
10.3.2. Argentina Dry Eye Syndrome Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Indication
10.3.2.2.2. By Product Type
10.3.2.2.3. By Dosage Form
10.3.2.2.4. By Type
10.3.2.2.5. By Distribution Channel
10.3.3. Colombia Dry Eye Syndrome Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Indication
10.3.3.2.2. By Product Type
10.3.3.2.3. By Dosage Form
10.3.3.2.4. By Type
10.3.3.2.5. By Distribution Channel
11. MIDDLE EAST AND AFRICA DRY EYE SYNDROME TREATMENT MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Indication
11.2.2. By Product Type
11.2.3. By Dosage Form
11.2.4. By Type
11.2.5. By Distribution Channel
11.2.6. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Dry Eye Syndrome Treatment Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Indication
11.3.1.2.2. By Product Type
11.3.1.2.3. By Dosage Form
11.3.1.2.4. By Type
11.3.1.2.5. By Distribution Channel
11.3.2. Saudi Arabia Dry Eye Syndrome Treatment Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Indication
11.3.2.2.2. By Product Type
11.3.2.2.3. By Dosage Form
11.3.2.2.4. By Type
11.3.2.2.5. By Distribution Channel
11.3.3. UAE Dry Eye Syndrome Treatment Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Indication
11.3.3.2.2. By Product Type
11.3.3.2.3. By Dosage Form
11.3.3.2.4. By Type
11.3.3.2.5. By Distribution Channel
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
13.1. Recent Developments
13.2. Mergers & Acquisitions
13.3. Product Launches
14. COMPETITIVE LANDSCAPE
14.1. Business Overview
14.2. Product Offerings
14.3. Recent Developments
14.4. Financials (As Reported)
14.5. Key Personnel
14.6. SWOT Analysis
14.6.1. Johnson & Johnson
14.6.2. AbbVie Inc.
14.6.3. Bausch Health Companies Inc.
14.6.4. Novartis AG
14.6.5. Sun Pharmaceuticals Industries Limited
14.6.6. Santen Pharmaceutical Co., Ltd.
14.6.7. Otsuka Pharmaceutical Co., Ltd.
14.6.8. Oyster Point Pharma, Inc.
14.6.9. Alcon Inc.
14.6.10. GlaxoSmithKline plc.
15. STRATEGIC RECOMMENDATIONS
